# Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run

> **Open Intelligence Dossier** · First detected: 2026-10-09 03:20 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Investor's Business Daily, Reuters, Yahoo Finance and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Investor's Business Daily | Former Highflying Biotech Hits The Skids On A Surprise Failure | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxQeUpIaVlRRUIyazhNY3M0b2h3bDM3a1JDVGhMdWhDN1ZsblZKaHA5M0t0TllPbVYyd3NDX1VuQWQ5a29SVldBZ3cwSlVDVHlfWmdjUzJRM3lUd2RnUU01X3lVdFlicjFJTWlYZXFuUTJjUjBwQkJXMEhnM3FjYk5LSmZrLXBNOVU?oc=5) |
| Reuters | Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxOQ1VGX3BsbGNLQnZJRXBEeURjdmVpS2p0OVM2NDhpRnZMVElONjhQTnBuUHc1azFUdEJMN1JKc01IZTdiX0ZNME5sZmFYUVJVY0UtRWg5eTRyVHZBT182Z2h4LTNNOTd5cTVrWF9rTjBIVU5UWUVMWGxsZXJUVHE3XzV1WWlkYmpMUGo1MHc3WmpYc0Q4UEg0Ykl1eU5rbnRFNGZCZFlncmhGZHJicElPZXBJX3dJRVk?oc=5) |
| Yahoo Finance | Why Is ARGX Stock Plunging Today? | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQbE42LUxSY3FrTlBHSlZMVzRFR0V3bWZnd0EzUnlTMkFiay01MkN6QnZnbk1Qel9WRFoteFNBbWUtRFk3T1VhWnhHbmMwWlRRSmRVTXllWUgxV1FNQ2hBU1JWNFN5SFE2Rl9mSzVsX1NKZ1BjOUttSUZLRWlaWVhtYWVqS3NVcmpKVGt4MDNBRjF1dFcwMnFCamVB?oc=5) |
| STAT | Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxOdElDMHVUa0gzVThrS3lHYmNQZTB5V2x1RFJRR0tCbnR6R3BHVHNZOFcyT0dOcGlnb3hUQ0FWWS10bkNsLVlxQlNtQWp2N3NwZ0ZjSU1iUE9HWXlYeHJjVGh3VE5jcER6RnJ3a2lLMHBsT2tyYjB1R3BLeUxmUnJRRXpsbw?oc=5) |
| Fierce Biotech | Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNWmJhclVnMm8yZHJUMkkxSnc1UmNIb1o0QlBteXRDR3hPa1ppRkNpWEI5YzFreE5yVlZlS1VFbjR1TXNnOGVxR1V6NFlycnRBZ1IwU0R3czhsRUMyOXl1WFhSQ0lPbk1xcFQ3U2lnWkozYzB0cWtUekpadUk5dEZHWTZqN2o2U3hja3UwVU1JWnlCZi1JN2RWWGttc1pPQ1k?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-10-09/argenx-digests-phase-2-celiac-win-for-2-2b-drug-preps-pivotal-run*